Aligos Therapeutics (ALGS) Cash & Current Investments (2021 - 2025)
Historic Cash & Current Investments for Aligos Therapeutics (ALGS) over the last 5 years, with Q3 2025 value amounting to $156.2 million.
- Aligos Therapeutics' Cash & Current Investments rose 3647.36% to $156.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $156.2 million, marking a year-over-year increase of 3647.36%. This contributed to the annual value of $56.9 million for FY2024, which is 5807.27% down from last year.
- As of Q3 2025, Aligos Therapeutics' Cash & Current Investments stood at $156.2 million, which was up 3647.36% from $227.2 million recorded in Q2 2025.
- In the past 5 years, Aligos Therapeutics' Cash & Current Investments registered a high of $242.2 million during Q3 2021, and its lowest value of $56.9 million during Q4 2024.
- Its 5-year average for Cash & Current Investments is $155.3 million, with a median of $156.2 million in 2025.
- Examining YoY changes over the last 5 years, Aligos Therapeutics' Cash & Current Investments showed a top increase of 9445.11% in 2024 and a maximum decrease of 5807.27% in 2024.
- Aligos Therapeutics' Cash & Current Investments (Quarter) stood at $190.7 million in 2021, then tumbled by 34.03% to $125.8 million in 2022, then grew by 7.93% to $135.8 million in 2023, then crashed by 58.07% to $56.9 million in 2024, then skyrocketed by 174.42% to $156.2 million in 2025.
- Its last three reported values are $156.2 million in Q3 2025, $227.2 million for Q2 2025, and $202.0 million during Q1 2025.